SPDR S&P Pharmaceuticals ETFXPH
XPH
0
Funds holding %
of 7,327 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
27% more capital invested
Capital invested by funds: $101M [Q4 2024] → $128M (+$27.4M) [Q1 2025]
11.68% more ownership
Funds ownership: 63.41% [Q4 2024] → 75.09% (+11.68%) [Q1 2025]
6% less funds holding
Funds holding: 72 [Q4 2024] → 68 (-4) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
50% less call options, than puts
Call options by funds: $569K | Put options by funds: $1.14M
Research analyst outlook
We haven’t received any recent analyst ratings for XPH.
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
XPH: Healthcare Dashboard For July
This article provides a top-down view of the healthcare sector based on valuation and quality metrics. Healthcare providers are the most undervalued subsector, while pharma/biotech has the best quality score. XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade.
Neutral
Seeking Alpha
2 months ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
Zacks Investment Research
2 months ago
ETFs on the Move Post U.S.-China Trade Deal
Let's delve into the ETF world following the 90-day U.S.-China trade deal.
Positive
Zacks Investment Research
2 months ago
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Negative
Benzinga
2 months ago
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.
Neutral
CNBC Television
3 months ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Market Watch
3 months ago
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.
Neutral
Seeking Alpha
5 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
Zacks Investment Research
11 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
Zacks Investment Research
1 year ago
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The SPDR S&P Pharmaceuticals ETF (XPH) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Charts implemented using Lightweight Charts™